GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kissei Pharmaceutical Co 4547.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

3,725

+1.64%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥97.41bn

FY2017FY2026

Net income

¥13.78bn

FY2017FY2026

Free cash flow

−¥6.37bn

FY2017FY2026

Shareholders' equity

¥230.15bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥97.41bn¥88.33bn¥75.58bn¥67.49bn¥65.38bn¥69.04bn¥63.23bn¥72.30bn¥74.01bn¥71.71bn
Gross profit¥45.82bn¥44.06bn¥37.34bn¥32.38bn¥31.24bn¥32.72bn¥34.91bn¥45.57bn¥48.12bn¥46.63bn
Research and development—¥12.89bn¥9.47bn¥10.39bn¥10.36bn¥9.63bn¥10.77bn¥15.71bn¥14.18bn¥13.88bn
Operating income−¥2.93bn¥5.77bn¥4.02bn−¥1.13bn−¥1.40bn¥1.50bn¥1.86bn¥6.20bn¥9.89bn¥8.49bn
Net income¥13.78bn¥11.96bn¥11.16bn¥10.53bn¥12.92bn¥5.29bn¥2.82bn¥5.48bn¥9.04bn¥7.73bn
Diluted earnings per share332.41288.55257.90234.28280.19114.6060.30117.33193.62159.91

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥275.09bn¥244.06bn¥260.93bn¥221.20bn¥238.09bn¥268.86bn¥231.79bn¥213.52bn¥213.09bn¥186.80bn
Cash and short-term investments¥54.42bn¥48.65bn¥45.93bn¥49.60bn¥53.15bn¥44.45bn¥59.67bn¥49.36bn¥47.66bn¥48.15bn
Total liabilities¥43.55bn¥33.93bn¥39.79bn¥26.39bn¥35.91bn¥48.91bn¥38.83bn¥30.82bn¥37.00bn¥29.02bn
Debt¥1.25bn¥1.60bn¥1.73bn¥1.81bn¥1.87bn¥2.05bn¥2.13bn¥3.96bn¥3.85bn¥3.53bn
Shareholders' equity¥230.15bn¥209.00bn¥220.03bn¥193.90bn¥201.38bn¥219.31bn¥192.46bn¥182.26bn¥175.70bn¥157.45bn
Shares outstanding41m41m43m45m46m46m47m47m47m48m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥1.49bn¥6.52bn−¥1.68bn−¥6.68bn¥1.53bn−¥2.54bn¥13.93bn¥6.35bn¥8.85bn¥6.44bn
Capital spending−¥4.88bn−¥4.51bn−¥1.20bn−¥2.55bn−¥1.92bn−¥1.49bn−¥1.30bn−¥1.09bn−¥1.87bn−¥1.20bn
Free cash flow−¥6.37bn¥2.01bn−¥2.88bn−¥9.23bn−¥386.0m−¥4.03bn¥12.63bn¥5.25bn¥6.98bn¥5.24bn
Dividends paid−¥4.84bn−¥3.80bn−¥3.72bn−¥3.13bn−¥2.54bn−¥2.48bn−¥2.38bn−¥2.29bn−¥2.27bn−¥2.20bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥23.39bn¥24.77bn¥26.80bn¥23.64bn¥22.19bn¥22.66bn¥23.20bn¥21.30bn
Gross profit¥11.43bn¥10.83bn¥12.30bn¥11.61bn¥11.08bn¥10.95bn¥11.72bn¥10.52bn
Operating income¥1.10bn¥756.0m¥3.15bn−¥8.95bn¥2.11bn¥1.53bn¥2.46bn−¥377.0m
Net income¥4.72bn¥2.76bn¥3.23bn¥3.27bn¥4.52bn¥3.12bn¥3.59bn¥1.14bn
Diluted earnings per share113.9466.6877.9278.77109.0275.2982.9926.41
Total assets¥270.24bn¥275.09bn¥259.61bn¥261.13bn¥243.67bn¥244.06bn¥248.93bn¥260.34bn
Cash and short-term investments¥52.95bn¥54.42bn¥46.73bn¥61.70bn¥48.75bn¥48.65bn¥44.46bn¥49.96bn
Debt¥1.25bn¥1.25bn¥1.27bn¥1.27bn¥1.28bn¥1.43bn¥1.28bn¥1.26bn
Shareholders' equity¥229.03bn¥230.15bn¥216.39bn¥211.38bn¥207.09bn¥209.00bn¥210.20bn¥219.66bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue13.0%7.1%3.2%
Operating income37.4%——
Net income9.4%21.1%5.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin48.4%48.5%48.3%54.7%
Operating margin1.5%1.7%1.3%5.2%
Net margin13.9%14.4%14.2%12.1%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings11.616.116.113.29.219.737.126.614.520.0
Price to sales1.62.22.42.11.81.51.62.01.82.1

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year105.00175.0086.0081.0068.0055.0053.0051.00
  • 1.1-for-1 split · 26 Mar 1996
  • 1.1-for-1 split · 28 Mar 1995
  • 1.1-for-1 split · 28 Mar 1994
  • 1.1-for-1 split · 26 Mar 1993
  • 1.1-for-1 split · 26 Mar 1992
  • 11-for-10 split · 26 Mar 1991

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.